SRNE Stock Price
SRNE RSI Chart
SRNE Valuation
SRNE Price/Sales (Trailing)
SRNE Profitability
SRNE Fundamentals
SRNE Revenue
SRNE Earnings
Price Action
Last 7 days
86.0%
Last 30 days
-71.3%
Last 90 days
-77.7%
Trailing 12 Months
-88.9%
SRNE Financial Health
SRNE Investor Care
Peers (Alternatives to Sorrento Therapeutics)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
GILD | 96.2B | 27.0B | -7.94% | 24.63% | 17.23 | 3.56 | -1.56% | 23.65% |
MRNA | 48.5B | 15.1B | -3.43% | -7.04% | 10.13 | 3.22 | -33.37% | -67.32% |
EXAS | 14.7B | 2.1B | 30.84% | 64.48% | -28.54 | 7.08 | 17.95% | 30.68% |
INCY | 14.0B | 3.4B | -14.89% | -17.68% | 43.03 | 4.11 | 13.67% | -65.23% |
| MID-CAP | ||||||||
EXEL | 6.2B | 1.7B | 3.69% | 5.17% | 40.44 | 3.74 | 9.41% | -48.42% |
SYNH | 4.3B | 5.4B | 10.29% | -42.16% | 28.89 | 0.79 | 1.37% | -38.84% |
DNLI | 4.1B | - | 22.94% | 24.01% | -11.06 | 37.77 | 122.90% | -29.67% |
ARWR | 3.6B | 272.8M | -5.41% | 0.81% | -23.91 | 13.16 | 3.56% | -34.35% |
| SMALL-CAP | ||||||||
AVXL | 747.8M | - | 13.11% | 2.87% | -14.18 | 291.16 | -34.21% | -22.02% |
NVAX | 622.2M | - | -4.25% | -84.68% | -0.54 | 0.31 | 72.89% | 12.32% |
PGEN | 311.7M | 23.2M | 7.96% | -8.27% | 12.55 | 13.41 | -45.75% | 126.39% |
SRNE | 170.9M | - | -71.28% | -88.95% | -0.25 | 2.64 | 22.40% | -42.61% |
NNVC | 12.9M | - | -17.16% | -46.38% | -1.9 | - | - | 19.06% |
TENX | 7.1M | - | -0.31% | -97.29% | -0.39 | - | - | 71.01% |
Financials for Sorrento Therapeutics
| Income Statement (Last 12 Months) | ||||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
| Revenue | -100.0% | 64,752,000 | 60,322,000 | 54,984,000 | 57,034,000 | |
| S&GA Expenses | 5.7% | 192,739,000 | 182,337,000 | 197,302,000 | 195,632,000 | 197,789,000 |
| Costs and Expenses | -0.5% | 564,481,000 | 567,154,000 | 509,618,000 | 496,224,000 | 480,463,000 |
| EBITDA | 4.8% | -507,267,000 | -533,041,000 | -480,304,000 | - | - |
| EBITDA Margin | 13.3% | -8.41 | -9.69 | -8.42 | - | - |
| Earnings Before Taxes | -18.5% | -665,590,000 | -561,747,000 | -529,315,000 | -557,386,000 | -504,105,000 |
| EBT Margin | 13.4% | -8.77 | -10.14 | -8.84 | - | - |
| Interest Expenses | -24.7% | 6,457,000 | 8,574,000 | 9,297,000 | 11,405,000 | 11,107,000 |
| Net Income | -17.4% | -672,362,000 | -572,843,000 | -494,011,000 | -524,238,000 | -471,459,000 |
| Net Income Margin | 14.0% | -8.19 | -9.53 | -8.27 | - | - |
| Free Cahsflow | 5.9% | -308,998,000 | -328,279,000 | -326,594,000 | - | - |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
| Assets | -2.7% | 460 | 473 | 616 | 632 | 856 |
| Current Assets | 4.6% | 101 | 96.00 | 177 | 196 | 331 |
| Cash Equivalents | 59.3% | 38.00 | 24.00 | 71.00 | 70.00 | 112 |
| Inventory | 13.3% | 11.00 | 10.00 | 18.00 | 21.00 | 14.00 |
| Net PPE | 5.6% | 55.00 | 52.00 | 44.00 | 43.00 | 42.00 |
| Goodwill | 0% | 80.00 | 80.00 | 80.00 | 81.00 | 80.00 |
| Liabilities | 18.8% | 587 | 495 | 485 | 496 | 629 |
| Current Liabilities | -49.5% | 166 | 328 | 202 | 145 | 204 |
| LT Debt, Current | 204.8% | 50.00 | 16.00 | 53.00 | 24.00 | 57.00 |
| LT Debt, Non Current | 11.9% | 21.00 | 19.00 | 18.00 | 83.00 | 96.00 |
| Shareholder's Equity | -488.0% | -127 | -21.67 | 132 | 136 | 226 |
| Retained Earnings | -7.1% | -2,099 | -1,959 | -1,735 | -1,646 | -1,427 |
| Additional Paid-In Capital | 1.6% | 2,021 | 1,989 | 1,917 | 1,827 | 1,704 |
| Shares Outstanding | 5.4% | 551 | 523 | 468 | 436 | 375 |
| Minority Interest | 37.3% | -1.92 | -3.06 | -1.64 | 4.00 | -0.34 |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
| Cashflow From Operations | 11.5% | -259 | -293 | -297 | -319 | -317 |
| Share Based Compensation | -3.4% | 72.00 | 75.00 | 80.00 | 83.00 | 87.00 |
| Cashflow From Investing | 53.8% | -13.17 | -28.52 | -25.69 | -12.20 | 68.00 |
| Cashflow From Financing | -36.0% | 200 | 312 | 357 | 326 | 319 |
Risks for SRNE
What is the probability of a big loss on SRNE?
100%
Probability that Sorrento Therapeutics stock will be more than 20% underwater in next one year
100%
Probability that Sorrento Therapeutics stock will be more than 30% underwater in next one year.
100%
Probability that Sorrento Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does SRNE drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Sorrento Therapeutics was unfortunately bought at previous high price.
Drawdowns
Returns for SRNE
Cumulative Returns on SRNE
-23.9%
10-Year Cumulative Returns
-35.0%
7-Year Cumulative Returns
-49.2%
5-Year Cumulative Returns
-50.5%
3-Year Cumulative Returns
What are the long-term rolling returns for SRNE?
FIve years rolling returns for Sorrento Therapeutics.
Annualized Returns
Which funds bought or sold SRNE recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-05-23 | Front Row Advisors LLC | sold off | -100 | - | - | -% |
2023-05-22 | AMERIPRISE FINANCIAL INC | sold off | -100 | -82,000 | - | -% |
2023-05-19 | Coppell Advisory Solutions LLC | sold off | -100 | -89.00 | - | -% |
2023-05-18 | NEW YORK STATE COMMON RETIREMENT FUND | sold off | -100 | -235,000 | - | -% |
2023-05-18 | CENTAURUS FINANCIAL, INC. | sold off | -100 | -36,000 | - | -% |
2023-05-18 | JPMORGAN CHASE & CO | reduced | -100 | -2,738,000 | - | -% |
2023-05-17 | B. Riley Wealth Advisors, Inc. | sold off | -100 | -10,805 | - | -% |
2023-05-17 | Advisory Services Network, LLC | sold off | -100 | -789 | - | -% |
2023-05-16 | JANE STREET GROUP, LLC | sold off | -100 | -647,687 | - | -% |
2023-05-16 | Rockefeller Capital Management L.P. | sold off | -100 | -3,000 | - | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Sorrento Therapeutics News
Schedule 13G FIlings of Sorrento Therapeutics
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Mar 10, 2023 | state street corp | 0.03% | 156,800 | SC 13G/A | |
| Mar 08, 2023 | blackrock inc. | 0.0% | 75,749 | SC 13G/A | |
| Feb 17, 2023 | ics opportunities, ltd. | 2.4% | 11,376,140 | SC 13G | |
| Feb 09, 2023 | state street corp | 10.73% | 50,637,571 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 6.26% | 29,535,954 | SC 13G/A | |
| Feb 03, 2023 | blackrock inc. | 8.4% | 39,423,641 | SC 13G/A | |
| Jul 11, 2022 | state street corp | 10.20% | 39,661,099 | SC 13G | |
| Feb 10, 2022 | vanguard group inc | 5.12% | 15,692,730 | SC 13G | |
| Feb 07, 2022 | blackrock inc. | 6.9% | 21,775,865 | SC 13G/A | |
| Feb 02, 2021 | blackrock inc. | 6.7% | 17,619,678 | SC 13G |
SRNE Fair Value
Recent SEC filings of Sorrento Therapeutics
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| May 19, 2023 | 8-K | Current Report | |
| May 15, 2023 | 10-Q | Quarterly Report | |
| May 15, 2023 | 8-K | Current Report | |
| May 12, 2023 | POS AM | POS AM | |
| May 09, 2023 | NT 10-Q | NT 10-Q | |
| May 03, 2023 | 8-K | Current Report | |
| Apr 26, 2023 | 8-K | Current Report | |
| Apr 20, 2023 | 8-K | Current Report | |
| Apr 20, 2023 | 8-K | Current Report | |
| Apr 12, 2023 | 25-NSE | 25-NSE |
Latest Insider Trading transactions for SRNE
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2022-12-21 | Ji Henry | acquired | 1,650 | 5.5 | 300 | see remarks |
2022-12-15 | Ji Henry | acquired | - | - | 1,500,000 | see remarks |
2022-12-02 | Ji Henry | acquired | 1,100 | 5.5 | 200 | see remarks |
2022-09-07 | Ji Henry | bought | 179,349 | 2.0177 | 88,888 | see remarks |
2022-09-06 | Ji Henry | bought | 108,882 | 1.9599 | 55,555 | see remarks |
2022-09-02 | Ji Henry | acquired | - | - | 2,500,000 | see remarks |
2022-08-26 | Ji Henry | bought | 70,332 | 2.11 | 33,333 | see remarks |
2022-08-25 | Ji Henry | bought | 45,768 | 2.0596 | 22,222 | see remarks |
2022-06-14 | Ji Henry | bought | 13,999 | 1.3999 | 10,000 | see remarks |
2021-12-27 | Janda Kim | sold | -17,640 | 5.88 | -3,000 | - |
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 94 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California.
SRNE Income Statement
2023-03-31Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
|---|---|---|
Mar. 31, 2023 | Mar. 31, 2022 | |
| Revenues: | ||
| Revenues | $ 16,251 | $ 18,385 |
| Operating costs and expenses: | ||
| Research and development | 43,805 | 63,977 |
| Acquired in-process research and development | 12,272 | |
| Selling, general and administrative | 54,980 | 44,327 |
| Intangible amortization | 1,127 | 1,034 |
| Increase (decrease) on contingent consideration | 3,800 | (2,100) |
| Loss on impairment of intangible assets | 11,900 | |
| Legal settlement | 1,797 | |
| Total operating costs and expenses | 122,595 | 125,268 |
| Loss from operations | (106,344) | (106,883) |
| (Loss) gain on derivative liabilities | (1,280) | 7,500 |
| (Loss) gain on marketable and equity investments | (13,683) | 68,534 |
| Loss on debt extinguishment, net | (40) | (5,262) |
| (Gain) loss on foreign currency exchange | (4) | 397 |
| Interest expense, net | (1,132) | (3,249) |
| Other (loss) income | (76) | 17 |
| Reorganization items, net | (20,231) | 0 |
| Loss before income tax | (142,790) | (38,946) |
| Income tax expense | 11,468 | 1,463 |
| Loss on equity method investments | (368) | (131) |
| Net loss | (154,626) | (40,540) |
| Net (loss) income attributable to noncontrolling interests | (15,010) | 275 |
| Net loss attributable to Sorrento | $ (139,616) | $ (40,815) |
| Net loss per share - basic per share attributable to Sorrento | $ (0.26) | $ (0.12) |
| Net loss per share - diluted per share attributable to Sorrento | $ (0.26) | $ (0.12) |
| Weighted-average shares used during period - basic shares attributable to Sorrento | 543,137 | 337,123 |
| Weighted-average shares used during period - diluted shares attributable to Sorrento | 543,137 | 337,123 |
| Product | ||
| Revenues: | ||
| Revenues | $ 10,597 | $ 9,990 |
| Operating costs and expenses: | ||
| Cost of products sold and services | 3,881 | 2,878 |
| Service | ||
| Revenues: | ||
| Revenues | 5,654 | 8,395 |
| Operating costs and expenses: | ||
| Cost of products sold and services | $ 1,305 | $ 2,880 |
SRNE Balance Sheet
2023-03-31Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 37,655 | $ 23,634 |
| Marketable investments | 12,662 | 26,344 |
| Accounts receivables, net | 26,524 | 24,469 |
| Inventory | 11,308 | 9,976 |
| Prepaid expenses | 7,827 | 8,807 |
| Other current assets | 4,784 | 3,143 |
| Total current assets | 100,760 | 96,373 |
| Property and equipment, net | 54,861 | 51,971 |
| Operating lease right-of-use assets | 85,398 | 86,464 |
| Intangibles, net | 123,875 | 136,902 |
| Goodwill | 80,269 | 80,269 |
| Equity investments | 12,008 | 17,176 |
| Other assets, net | 2,892 | 3,685 |
| Total assets | 460,063 | 472,840 |
| Current liabilities: | ||
| Accounts payable | 14,590 | 47,515 |
| Accrued payroll and related benefits | 5,314 | 7,884 |
| Accrued expenses and other current liabilities | 68,855 | 58,456 |
| Accrued legal settlements | 174,752 | |
| Current portion of deferred revenue | 252 | 652 |
| Current portion of operating lease liabilities | 14,050 | 13,880 |
| Current portion of contingent consideration | 397 | 397 |
| Acquisition consideration | 391 | 7,800 |
| Income tax payable | 12,148 | 300 |
| Current portion of debt | 49,635 | 16,286 |
| Total current liabilities | 165,632 | 327,922 |
| Long-term debt, net of discount | 21,400 | 19,130 |
| Deferred tax liabilities, net | 238 | 591 |
| Deferred revenue | 983 | 7,098 |
| Derivative liabilities | 1,580 | 300 |
| Operating lease liabilities | 84,462 | 85,208 |
| Contingent consideration | 550 | 48,949 |
| Other long-term liabilities | 3,428 | 5,311 |
| Total liabilities not subject to compromise | 278,273 | 494,509 |
| Liabilities subject to compromise | 309,210 | |
| Total liabilities | 587,483 | 494,509 |
| Commitments and contingencies (See Note 10) | ||
| Sorrento Therapeutics, Inc. equity (deficit) | ||
| Common stock, $0.0001 par value 750,000,000 shares authorized and 551,281,154 and 522,817,137 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively | 55 | 52 |
| Additional paid-in capital | 2,021,148 | 1,988,753 |
| Accumulated other comprehensive income | 1,826 | 1,501 |
| Accumulated deficit | (2,099,063) | (1,959,447) |
| Treasury stock, 7,568,182 shares at cost at March 31, 2023, and December 31, 2022 | (49,464) | (49,464) |
| Total Sorrento Therapeutics, Inc. stockholders' equity (deficit) | (125,498) | (18,605) |
| Noncontrolling interests | (1,922) | (3,064) |
| Total equity (deficit) | (127,420) | (21,669) |
| Total liabilities and stockholders' equity (deficit) | $ 460,063 | $ 472,840 |